Evernorth EncircleRx℠

Discover EncircleRx, a data-driven portfolio that helps plan sponsors reduce costs and enhance outcomes. EncircleRx: Cardiodiabesity gives clients optionality and predictability in managing cardiodiabesity—obesity, diabetes and cardiovascular disease—with the first-ever GLP-1 financial guarantee from a PBM.

Hero

EncircleRx can help you manage the cost of GLP-1s

EncircleRx: Cardiodiabesity offers the PBM industry's first financial guarantee, giving plans the tools to better control GLP-1 growth and expand access.

Learn more
woman
EncircleRx: Cardiodiabesity is addressing growing GLP-1 demand

Since launching, EncircleRx has saved clients about $50 million in plan savings by managing costs, improving outcomes and preventing fraud.

Read how EncircleRx helps plan sponsors achieve peace of mind
CARDIODIABESITY:

The connection linking obesity, diabetes and cardiovascular disease

Many Americans struggle with obesity and are seeking new ways to lose weight to improve their overall health, even if it means using off-label medications which are in short supply for those who desperately need them.

Of those diagnosed with type 2 diabetes, 77% have high cholesterol and/or high blood pressure, putting them at risk for a third, potentially fatal comorbidity: cardiovascular disease.2
Up to
53%
of new type 2 diabetes cases in the U.S. today are linked to obesity, meaning that over half of diabetes cases could be prevented by more effective obesity treatment1
What is cardiodiabesity?

Cardiodiabesity is a hybrid term that describes the relationship between obesity, type-2 diabetes and cardiovascular disease. It’s becoming a widely recognized and urgent concern among health care researchers, providers, plans and most of all, patients.

Cardiodiabesity affects health care costs as one of the most expensive condition categories to treat

$173B

annual U.S. medical costs for obesity3

$413B

the cost of diagnosed diabetes yearly4

$252B

annual cost of health care services, medications and productivity loss due to heart disease5

Cardiodiabesity is complicated…but its benefits management doesn’t have to be.

Addressing the complexity of these conditions requires a tailored, data-driven and innovative approach to both decrease pharmacy spend and save lives.

VIDEO

Navigating cardiodiabesity

Evernorth EncircleRx provides solutions and tools to turn insights into opportunities. 

Cardiodiabesity is the first solution from the EncircleRx portfolio and provides optionality to manage trend and improve patient outcomes.

Evernorth’s transparent, proactive and innovative capabilities come together to help plans manage cardiodiabesity, unlocking a benefit that tackles this high-cost and highly prevalent disease category in a more streamlined way.

Tackling the GLP-1 Trend

GLP-1s are effective in treating the progression of diseases that stem from obesity: diabetes and cardiovascular disease. The GLP-1 class of drugs is on tap to be the number one trend for plans this year. In fact, J.P. Morgan Research forecasts that the GLP-1 market will exceed $100B by 2030, driven equally by diabetes and obesity usage.6

Clients want to make weight loss coverage part of the benefit, but are unsure of how to navigate this costly landscape.

women

The first-ever GLP-1 financial guarantee available from a PBM

EncircleRx now offers financial guarantees to provide plans with greater predictability and control of GLP-1 spend through a cost cap or savings guarantee depending on client type. 

Learn about our GLP-1 management capabilities

Meeting

Changing the narrative with enhanced care delivery

Managing GLP-1s for weight loss and diabetes is just one component of EncircleRx.

Close gaps in care

and delay or prevent the onset of comorbid conditions, reducing the need for interventions.

Combat costs

with personalized recommendations that identify both clinical and financial opportunities during treatment of these costly conditions. 

Improve outcomes

through a combination of plan design, innovative measures and utilization management considerations.

Explore more about cardiodiabesity and GLP-1s
""
Article
GLP-1s and digital support: A winning combination
January 24, 2024
Read the article
""
Article
Easing the impact of GLP-1s
January 11, 2024
Read the article
""
Article
Chronic conditions: The impact of delayed detection
December 19, 2023
Read the article

Want to learn more?

Please contact your account representative or consultant relations director to learn how Evernorth can help provide optionality in managing cardiodiabesity trend.

Sources

1. American Heart Association, 2021. Quantifying the Sex‐Race/Ethnicity‐Specific Burden of Obesity on Incident Diabetes Mellitus in the United States
2. 2023 Drug Trend Report data.
3. CDC, 2024, Adult Obesity Facts
4. CDC, 2024, Diabetes Basics
5. CDC, 2024, Heart Disease Facts
6. J.P. Morgan, 2023. The increase in appetite for obesity drugs